|1.||Levin, O S: 4 articles (01/2013 - 01/2006)|
|2.||Hauser, Robert A: 4 articles (07/2009 - 01/2004)|
|3.||Klivényi, Péter: 2 articles (05/2009 - 01/2008)|
|4.||Vécsei, László: 2 articles (05/2009 - 01/2008)|
|5.||Batysheva, T T: 2 articles (11/2008 - 01/2007)|
|6.||Babina, L A: 2 articles (11/2008 - 01/2007)|
|7.||Shikhkerimov, R K: 2 articles (11/2008 - 01/2007)|
|8.||Minaeva, N G: 2 articles (11/2008 - 01/2007)|
|9.||Kostenko, E V: 2 articles (11/2008 - 01/2007)|
|10.||Khozova, A A: 2 articles (11/2008 - 01/2007)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/2008 - "Despite the increase in cost, the use of stalevo in the treatment of Parkinson's disease with motor fluctuations is cost-effective in long-term (already after two years) management of patients."
01/01/2008 - "An open randomized study of pharmacoeconomic efficacy of stalevo in patients with Parkinson's disease with motor fluctuations was conducted. "
01/01/2008 - "[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations]."
01/01/2014 - "To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson's disease (PD). "
01/01/2014 - "[The use of stalevo in the treatment of patients with Parkinson's disease]."
|2.||Hypotension (Low Blood Pressure)
01/01/2006 - "The authors studied 15 patients with PD, aged 55.6+/-8.7 years, illness duration 7.7+/-3.1 years, who received stalevo during 6 weeks and revealed that stalevo reduced significantly the intensity of main PD symptoms, especially hypotension and rigidity as well as motor fluctuations, and improved general movement and daily activity of patients thus ameliorating their quality of life. "
02/01/2011 - "Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint."
01/01/2009 - "Switching from conventional levodopa to stalevo is efficacy and safety and can significantly improve QOL PD patients with fluctuations and dyskinesias."
01/01/2013 - "[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]."
04/01/2013 - "The controlled trial Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) reported an unexpected increase in acute myocardial infarction (AMI) with entacapone use in patients with Parkinson's disease (PD). "
01/01/2010 - "Additionally, the STalevo Reduction In Dyskinesia Evaluation (STRIDE-PD) study was designed with the aim of demonstrating that the combination of levodopa, carbidopa, and entacapone, used as initial levodopa therapy, significantly delays the onset of dyskinesias compared with the conventional levodopa/carbidopa formulation. "
08/01/2008 - "[Stalevo-associated lymphocytic colitis]."
|2.||Levodopa (L Dopa)
|4.||levodopa drug combination carbidopa (Nakom)
|5.||Catechol O-Methyltransferase (Methyltransferase, Catechol)
|6.||Dopamine Receptors (Dopamine Receptor)